On the role of bradykinin in secretion from vascular endothelial cells

Bradykinin will induce, in perfused rat hindlegs, the acute release from endothelial cells of tissue-type plasminogen activator and of von Willebrand factor. This release is mediated by B2-receptors, requires the influx of extracellular calcium, and is modulated by cyclic nucleotides. A possible role of bradykinin in the physiological regulation of plasma levels of tissue-type plasminogen activator is discussed. Chemicals/CAS: 1,4 dihydro 2,6 dimethyl 5 nitro 4 [2 (trifluoromethyl)phenyl] 3 pyridinecarboxylic acid methyl ester, 71145-03-4; 3,4,5 trimethoxybenzoic acid 8 (diethylamino)octyl ester, 57818-92-5; 8 bromo cyclic AMP, 23583-48-4; 8 bromo cyclic GMP, 31356-94-2; atrial natriuretic factor, 85637-73-6; bradykinin, 58-82-2, 5979-11-3; calcium, 7440-70-2; calmidazolium, 57265-65-3, 95013-41-5; diltiazem, 33286-22-5, 42399-41-7; forskolin, 66575-29-9; nitroprusside sodium, 14402-89-2, 15078-28-1; tissue plasminogen activator, 105913-11-9; trifluoperazine, 117-89-5, 440-17-5; verapamil, 152-11-4, 52-53-9; von Willebrand factor, 109319-16-6; 8-Bromo Cyclic Adenosine Monophosphate, 23583-48-4; 8-bromocyclic GMP, 31356-94-2; Atrial Natriuretic Factor, 85637-73-6; Bradykinin, 58-82-2; Calcium Channel Blockers; Calcium, 7440-70-2; Cyclic AMP, 60-92-4; Cyclic GMP, 7665-99-8; Forskolin, 66428-89-5; Nitroprusside, 15078-28-1; Receptors, Bradykinin; Receptors, Neurotransmitter; Tissue Plasminogen Activator, EC 3.4.21.68; von Willebrand Facto